Cellectis (CLLS) EBT Margin (2015 - 2026)
Cellectis (CLLS) recorded quarterly EBT Margin of 152.85% in Q1 2026, up 82.02% quarter-over-quarter from 849.91% in Q4 2025, and down 17504.0% on a YoY basis from N/an in Q1 2025.
Cellectis (CLLS) EBT Margin (2015 - 2026) Analysis & Trends
Cellectis' EBT Margin history runs 12 years deep, the most recent figure standing at 152.85% for Q1 2026.
- In Q1 2026, EBT Margin fell 17504.0% year-over-year to 152.85%; the TTM figure through Mar 2026 stood at 12.54% (down 1682.0% YoY), while the FY2025 annual figure was 93.24%, down 1855.0% from the prior year.
- EBT Margin was 152.85% for Q1 2026 at Cellectis, up from 849.91% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 357.8% in Q2 2024 to a low of 31081.27% in Q4 2023.
- Historically, EBT Margin has averaged 3813.08% across 5 years, with a median of 275.81% in 2024.
- The sharpest annual moves came in 2023 and 2024: EBT Margin tumbled 3106357 bps in 2023, then soared 3080546 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 17.7% in 2022, then sank by 175454 bps to 31081.27% in 2023, then soared by 99 bps to 275.81% in 2024, then slumped by 208 bps to 849.91% in 2025, then soared by 82 bps to 152.85% in 2026.
- The last three EBT Margin figures came in at 152.85% (Q1 2026), 849.91% (Q4 2025), and 94.0% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -152.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -152.85% |
| Dec 31, 2025 | -849.91% |
| Sep 30, 2025 | 94.00% |
| Jun 30, 2025 | 129.67% |
| Mar 31, 2025 | 22.20% |
| Dec 31, 2024 | -275.81% |
| Sep 30, 2024 | 212.14% |
| Jun 30, 2024 | 357.80% |
| Mar 31, 2024 | 257.33% |
| Dec 31, 2023 | -31,081.27% |
| Sep 30, 2023 | -9,114.84% |
| Jun 30, 2023 | -4,121.91% |
| Mar 31, 2023 | -12,574.82% |
| Dec 31, 2022 | -17.70% |
| Sep 30, 2022 | -6,346.86% |
| Jun 30, 2022 | -1,022.11% |
| Mar 31, 2022 | -337.48% |
| Dec 31, 2021 | -68.77% |
| Sep 30, 2021 | -509.72% |
| Jun 30, 2021 | -335.37% |